Impact Factor 3.845 | CiteScore 3.92
More on impact ›
"Excluding translational animal models and preclinical development studies, our mission is to provide a broad forum for discussion of topics of interest in Pharmaceutical Medicine and Outcomes Research"
Pharmaceutical Medicine and Health-and-Economic Outcomes Research are at the heart of the pharmacology field. The growing complexity and changing environment of global medicines development requires integrated medicines development from discovery to life-cycle management. The complex biological mechanisms, patient-centered endpoints and Health-Related Quality of Life outcomes have an increasingly important role in informing health policy and regulatory decision making in the rapidly changing health care funding and reimbursement systems.
Though studies involving translational animal models and preclinical development studies will not be considered for publication in this Specialty Section, our mission is to provide a broad forum for discussion of topics of interest in Pharmaceutical Medicine and Outcomes Research i.e. Pharmaceutical Medicine practice standards, medicines development sciences, and competency-based education and training - Health-Related Quality of Life impact measurement and Patient-Reported Outcome Measures (PROMs) research - Economic evaluations of costs and outcomes of health care interventions such as medicines, devices, diagnostics, procedures, and public health interventions - Medicines Utilization and Health Technology Assessment research - Health-and-economic impact of public health interventions focused on nutrition.
Frontiers especially acknowledges the exceptional contribution made by the former Chief Editor, Prof Dominique Dubois.
Guidelines for the conception and review of submissions to this Specialty Section of Frontiers in Pharmacology:
Preclinical development studies will not be considered for review.
Studies involving translational animal models will not be considered for review.
Clinical studies on medicines which are yet to be licensed by the FDA or EMA will not be considered for review, including traditional medical products whose clinical efficacy has not been sufficiently demonstrated.
Meta-analysis approaches will only be accepted as a component of more general studies, where methods to produce data sets have been comprehensively reported i.e Systematic Reviews.
Indexed in: PubMed, PubMed Central, Scopus, Web of Science, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS)
PMCID: all published articles receive a PMCID
Pharmaceutical Medicine and Outcomes Research welcomes submissions of the following article types: Brief Research Report, Clinical Trial, Correction, Curriculum, Instruction, and Pedagogy, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Policy and Practice Reviews, Policy Brief, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Pharmaceutical Medicine and Outcomes Research, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact email@example.com
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact firstname.lastname@example.org